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ajor adverse cardiovascular events associated with PCI in these patients.
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ere randomly assigned 2:1 to either the Interceptor PLUS (n  533) or control distal-protection
evices (GuardWire [n  191], FilterWire EZ [n  73]) at the physician’s discretion.
esults The trial primary clinical end point (composite occurrence of death, myocardial infarction, or
rgent repeat revascularization through 30 days) was observed in 8% and 7.3% of Interceptor and control-
reated patients, respectively (p  0.025 for noninferiority; p  0.77 for difference). Key secondary end
oints for device and procedural success were similar between randomly assigned treatment strategies.
onclusions The Interceptor PLUS Coronary Filter System is noninferior in safety and efﬁcacy to 30 days
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249utologous saphenous veins remain a common source of
onduit for use in surgical coronary bypass graft revascular-
zation (CABG) procedures. Within 10 years of CABG,
alf of venous grafts may become severely diseased or
ccluded (1–3). Repeat CABG is associated with greater
rocedural risk, less durable graft patency, and less symp-
omatic improvement when compared with the initial sur-
ical procedure (4,5). Saphenous vein graft (SVG) athero-
See page 265
clerotic plaque is frequently complex, friable and may be
ssociated with thrombus. Percutaneous coronary interven-
ion (PCI) with either balloon angioplasty or stent deploy-
ent may be associated with a high (47% to 54%) incidence
f enzymatic myocardial infarction (MI), including large
5 times upper limit of normal for creatine kinase [CK]-
yocardial band [MB]) infarctions in 16% to 18% of
rocedures (6,7). Both periprocedural MI and reduced
ntegrade graft flow (“no reflow”) have been ascribed to
mbolization of atherothrombotic debris and distal micro-
ascular occlusion (1,4,8–12). By using a distal balloon
cclusion-aspiration device (GuardWire, Medtronic Vascu-
ar, Santa Rosa, California) to trap and retrieve particulate
ebris, Webb et al. (10) identified particulate matter in 21 of
3 SVG angioplasty procedures. In the pivotal multicenter
AFER (Saphenous vein graft Angioplasty Free of Emboli
andomized) trial of 801 patients undergoing percutaneous
VG interventions, deployment of the GuardWire device was
ssociated with a 42% relative reduction in major adverse
ardiac events (MACEs) at 30 days after stenting when
ompared with conventional (no embolic protection) PCI
9.6% GuardWire vs. 16.5% control; p  0.004) (13). The
otential advantage of catheter-based filter devices as an
lternative approach to capture and retrieve atherothrombotic
ebris is the maintenance of coronary blood flow with en-
anced clinical stability and patient tolerance. In a multicenter
andomized trial involving 651 patients undergoing percuta-
eous intervention of 682 SVG lesions, a catheter-based filter
evice (FilterWire EZ, Boston Scientific, Natick, Massachu-
etts) demonstrated similar efficacy to the GuardWire device
ith respect to the occurrence of MACE to 30 days (9.9% vs
1.6%, respectively; p  0.0008 for noninferiority) (14).
owever, filter devices may differ in their crossing profile,
bility to circumferentially appose the target conduit, efficiency
f particulate capture, and ability to maintain conduit flow
hich is, in large part, determined by the open pore area of the
eployed device (15). The purpose of the AMEthyst (Assess-
ent of the Medtronic AVE Interceptor Saphenous Vein
raft Filter System) trial was to determine the relative safety
nd efficacy of a novel catheter-based filter device (the Inter-
eptor PLUS Coronary Filter System; Medtronic Vascular)
hen compared with Food and Drug Administration (FDA)- lpproved, commercially available distal protection devices (the
uardWire and the FilterWire EZ devices) when used as an
djunct to PCI with or without stenting, of degenerative
aphenous vein bypass grafts.
ethods
atient selection. Between July 2003 and April 2007, 797
atients were enrolled at 73 U.S. sites. Eligible patients were
t least 18 years of age with symptomatic ischemic heart
isease due to a target lesion with 50% (but 100%)
iameter stenosis of at least 1 SVG with a reference vessel
iameter of 2.5 and 5.25 mm, and a Thrombolysis In
yocardial Infarction (TIMI) flow grade1. Percutaneous
oronary intervention could be performed on as many as 2
VGs per patient, with no limit
o the number of target lesions
de novo or first-time restenotic
ith no previous stent deployed)
ttempted. Target lesion treat-
ent was limited to balloon an-
ioplasty and stent deployment.
ajor exclusion criteria included
llergy or contraindication to
tudy medications, stent materi-
ls, or contrast; acute MI, or
ecent (24 h) MI with total
K 2 times normal within the
ast 24 h and cardiac enzymes
CK-MB fraction) greater than
ormal limits at the time of
reatment; major surgery within
0 days; left ventricular ejection
raction 25%; serum creatinine
2.5 mg/dl (if not on chronic
emodialysis); stroke or tran-
ient ischemic attack within 2
onths; active peptic ulcer or
pper gastrointestinal bleeding
ithin 3 months; or history of bleeding diathesis or coagu-
opathy and concurrent medical condition with life expect-
ncy 12 months.
In addition to the target SVG-PCI, PCI of as many as 2
ontarget native coronary lesions was permitted during the
ndex procedure. Nontarget lesions were required to have
tenosis severity 50, but 100% with lesion length 24
m and reference vessel diameter 2.5 mm. Percutaneous
oronary intervention of nontarget lesions with the follow-
ng characteristics was not permitted: location distal to
ither the target SVG or other bypass graft, location distal
o a 45° bend in the vessel, moderate-to-severe calcifica-
ion; ostial or bifurcation lesions; an unprotected left main
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary bypass
graft surgery
CK  creatine kinase
DES  drug-eluting stent(s)
FDA  Food and Drug
Administration
GP  glycoprotein
ITT  intention to treat
MACE  major adverse
cardiovascular events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PP  per protocol
SVG  saphenous vein graft
TIMI  Thrombolysis In
Myocardial Infarction
TVR  target vessel
revascularizationesion; or evidence of thrombus.
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250Eligible patients agreed to all postprocedure follow-up
nd signed a written informed consent. The study protocol
as approved by the institutional review boards of all
articipating centers. An independent data and safety mon-
toring board performed a prespecified interim review of the
rst 300 randomized patients and again after completion of
he 30-day follow-up.
tudy devices. The Interceptor PLUS Coronary Filter Sys-
em consists of a steerable vascular filter, an actuator handle,
torque handle, a peel-away introducer, and a guidewire
ntroducer (Fig. 1). The vascular filter component comprises
he self-expanding and free-floating filter, constructed of
itinol and platinum-filled (for enhancement of radiopacity)
itinol wire and constrained between 2 mechanical stops on
steerable 0.014-inch diameter guidewire of 180 cm in
ength. The filter is deployed and collapsed by means of the
ctuator handle. After the filter is expanded, blood and
mbolic material pass through 4 large in-flow openings
1,400 m) located at the proximal end of the device. The
istal filter has numerous 100-m pores that provide
erfusion while trapping embolic debris.
The FilterWire EZ is also a catheter-based distal filtration
evice that incorporates a nonocclusive filter (pore size 110
m) in the shape of a windsock, mounted on a self-expanding
itinol loop, and fixed on its own guidewire. The FilterWire
Z is deployed through a 3.2-F delivery sheath and recaptured
ith a 4-F retrieval sheath (14,16). The difference in open pore
rea between the Interceptor PLUS and FilterWire EZ is
llustrated in Figure 2 and has been reported to be associated
ith a 60% difference in flow (in vitro) (15).
The GuardWire temporary occlusion-aspiration system
onsists of a guidewire incorporating a central inflation
umen, to which an elastomeric balloon is attached. The
Figure 1. Interceptor PLUS Coronary Filter System
Components of the Interceptor PLUS Coronary Filter System include: (A) actua
ployed ﬁlter on a 0.014-inch wire; and (C) expanded ﬁlter with 1,400- to 1,800
arrow).evice has a 2.8-F crossing profile, and contrast inflation of Ahe balloon arrests anterograde graft flow (13). The inter-
ention is then performed over the wire, liberated debris is
rapped proximal to the balloon and is aspirated through a
-F monorail export catheter before balloon deflation,
hich restores graft flow (13).
andomization and interventional protocol. Successful
reatment of eligible nontarget lesions was required before
tudy enrollment. Use of a platelet glycoprotein (GP)
Ib/IIIa receptor inhibitor was at the discretion of the
reating physician but was determined before randomiza-
ion, which was stratified by the intent for GP IIb/IIIa
eceptor inhibitor use in an attempt to ensure equal distri-
ution of adjunctive therapies in the 2 arms of the trial.
ligible patients meeting these conditions were enrolled and
andomized (in a 2:1 ratio) to receive either the Interceptor
LUS or 1 of the 2 control devices (GuardWire or Filter-
ire EZ, at the investigator’s discretion). During the trial,
uardWire was approved for PCI of SVG with reference
essel diameter 2.5 to 6.0 mm and FilterWire EZ was
pproved for SVG with reference vessel diameter 3.5 to 5.5
m. In patients with target SVG reference diameter 3.5
m randomized to the “control” device, the investigator was
nstructed by protocol to select GuardWire to ensure proper
evice sizing.
All patients received a loading dose of 325 mg of
onenteric-coated water-soluble aspirin, and either 300 mg
f clopidogrel or 500 mg of ticlopidine, unless the patient
as on a chronic thienopyridine therapy. A complete blood
ell count, blood urea nitrogen, and creatinine, in addition
o a pregnancy test (for women of childbearing age) were
btained within 7 days before the procedure, and CK
nzyme, CK-MB isoenzyme levels, and electrocardiogram
ECG) were obtained within 24 h before the procedure.
ndle for ﬁlter deployment and closure; (B) low proﬁle (2.7-F) of the unde-
roximal in-ﬂow openings (large arrow) and 100-m distal pores (smalltor ha
-m pfter the initial intravenous bolus of unfractionated heparin
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251dose per participating hospital standard), a baseline acti-
ated clotting time was obtained and monitored at 30-min
ntervals throughout the procedure with additional heparin
dministered as needed to maintain the activated clotting
ime 250 s for patients receiving concomitant GP IIb/IIIa
lockade and 300 s for those who did not.
Baseline and post-PCI angiography of the target vessel
as performed after intracoronary graft nitroglycerine ad-
inistration in at least 2 near-orthogonal views, which
howed the target lesion free of foreshortening or vessel
verlap. The assigned embolic protection device was de-
loyed according to the manufacturer’s instructions for use,
nd the target lesion was then treated with balloon angio-
lasty and/or stenting. The choice of drug-eluting (DES) or
are-metal stent (BMS) was at the discretion of the treating
hysician.
After the procedure, all patients were continued on a daily
aintenance dose of aspirin (81 to 325 mg) and patients
ho received stents were prescribed clopidogrel (75 mg
very day) or ticlopidine (250 mg twice a day) according to
he stent type (30 days for BMS and 3 to 6 months’
inimum for DES). An ECG, complete blood cell count,
lood urea nitrogen, and creatinine were performed 16 to
4 h after the procedure or before discharge. In addition,
K and CK-MB were measured at 6 to 8 h, 12 to 16 h, and
0 to 24 h after procedure. Clinical follow-up with ECG
as obtained at 30  5 days, with repeat blood testing and
ngiography repeated if clinically indicated.
Procedural angiograms were forwarded to an angio-
raphic core laboratory for independent review. Lesion
ength was defined as the axial extent of the lesion that
ontained a shoulder-to-shoulder lumen reduction by
Figure 2. Comparison of Filter Open-Pore Areas
Scanning electron microscopy of expanded (A) FilterWire EZ and (B) Intercept
FilterWire EZ (71% vs. 27%, respectively) and results in greater relative ﬂow (6020%. Thrombus was defined as none, haziness, small size tomprising one-half of the lumen diameter, moderate sized
omprising more than one-half but 2 lumen diameters,
nd large comprising more than 2 lumen diameters. Coro-
ary aneurysms were defined as a maximum lumen diameter
ithin the treatment zone that was 1.2 times larger than the
verage reference diameter of the vessel.
The degree of SVG degeneration was assessed using an
rdinal metric of the extent of lumen irregularities and
ctasia (20% of the reference normal segment) within the
VG that comprises 25% (SVG degeneration score 0),
6% to 50% (SVG degeneration score 1), 51% to 75% (SVG
egeneration score 2), or75% (SVG degeneration score 3)
f the total SVG length. Reference vessel diameter and
inimal lumen diameter were determined from 2 projec-
ions using an automated edge-detection algorithm (CMS
edis, Leiden, the Netherlands) (17). Electrocardiograms
ere interpreted by an independent core laboratory at the
arvard Clinical Research Institute. The clinical events
ommittee reviewed and adjudicated all clinical events, and
he data coordination also was performed by an independent
ore laboratory at the Harvard Clinical Research Institute.
tudy end points and statistical methods. The intention-to-
reat (ITT) sample consisted of all randomized patients
xcept for 1 patient, who consented after receiving protocol-
pecified medications (excluded from ITT per directive of
ite institutional review board) and 2 patients erroneously
andomized (not included per directive of the FDA [ITT n
797]). A per-protocol (PP) analysis included all random-
zed patients treated with the assigned device (n  719).
he study primary end point was the composite end point
f MACE at 30 days, (defined as the occurrence of death,
I, or repeat revascularization [CABG or PCI] of the
S devices. The open-pore area of the Interceptor PLUS exceeds that of the
easured in vitro.or PLUarget vessel). Myocardial infarction was defined as CK-MB
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252levation 3 times normal. Secondary end points included
n-hospital MACE; device success, defined as successful
elivery deployment and retrieval of the study device to the
arget site; clinical success, defined as device success with no
n-hospital MACE; and final TIMI flow grade.
The null hypothesis for this study was that the Intercep-
or PLUS Coronary Filter System would have a primary end
oint event rate greater than or equal to that of the control
evice (GuardWire or FilterWire EZ) plus a noninferiority
argin delta. The alternative hypothesis was that the
nterceptor PLUS would have a primary end point event
ate less than that of the control device plus a noninferiority
argin delta.
tatistical methods. The initial study sample size calculation
as made using the following assumptions: the 30-day
ACE rate for Interceptor and control groups would be
0% based on observations made in the SAFER and FIRE
rials (13,14); the power of the study would be 80%; the
-sided alpha error would be 5% and the noninferiority
argin delta would be 5.5% (as in the precedent FIRE trial)
14). On the basis of these assumptions, enrollment of 600
atients in a 2:1 ratio of the Interceptor PLUS (400
atients) to control (200 patients) was planned with enrich-
ent of the control population by borrowing data from the
UARDWIRE arm of the SAFER trial with the use of
ayesian methodology.
At the prescribed review by the Data and Safety Moni-
oring Board of the first 300 enrolled patients, the observed
0-day MACE rate was substantially 10%, raising con-
erns about both the adequacy of the proposed sample size
s well as the validity of borrowing control data from a study
SAFER) with a potentially different (i.e., greater-risk)
opulation. In conjunction with the FDA, the following
evised assumptions were made: 30-day MACE rate for the
ontrol and Interceptor device groups would be 6%; the
ower of the study would 80%; and the noninferiority
argin delta was set at 4.5%. In this context, by the use of
2:1 randomization and the Farmington-Manning ap-
roach (18) to assess noninferiority, the planned study
nrollment was increased to total 800 patients.
Categorical variables were tested by the use of appropriate
ontingency table analyses (exact or chi-square approxima-
ions), and continuous variables were tested with the Stu-
ent t test or Wilcoxon rank sum test, depending on variable
istributions. All statistical analyses were performed with
he use of SAS for Windows (versions 8 and 9; SAS
nstitute, Cary, North Carolina) and NCSS 2004–PASS
005 software (NCSS, Kaysville, Utah). The 95% confi-
ence intervals (CIs) for the treatment difference on the
rimary end point were 1-sided and used a significance level
f 0.05. Confidence intervals for the treatment difference on
ll other end points were 2-sided and used a significance
evel of 0.05. PAn analysis was conducted to compare the consistency of
reatment effect in patients with and without GP IIb/IIIa
nhibitor treatment. Logistic regression was used to assess
he significance of embolic protection treatment group by
P IIb/IIIa inhibitor treatment interaction on 30-day
ACE rate with the use of a 0.10 level of significance.
After enrollment and randomization of the first 54
atients using the Interceptor P2 filter system, the next-
eneration (Interceptor PLUS) device became available and
as deployed for the remaining 479 patients randomized to
he treatment group. Iterative improvements provided by
he Interceptor PLUS included lower crossing profile (2.7
s. 2.9 F), shorter distal landing zone requirement (7.5 vs.
.5 cm), no delivery or retrieval sheath requirement, and
apid exchange monorail catheter compatibility. The com-
arability of the Interceptor P2 and PLUS subgroups was
onfirmed by analysis of baseline characteristics and 30-day
ACE rates in the ITT populations, and these groups were
ooled for the final analysis, which compared all Interceptor
evice(s) to the control device.
esults
atient population. A total of 800 patients were enrolled
nd randomized to either the Interceptor arm (n  533) or
ontrol (n  264) treatment arm. In the control group, 191
atients received GuardWire and 73 received FilterWire
Z device treatment. No differences in baseline clinical
emographic parameters were observed between the Inter-
eptor and control groups. A high prevalence of diabetes,
ypertension, and dyslipidemia was observed in both treat-
ent groups, and 10% of both groups had previous
alloon angioplasty to the target lesion (Table 1). Baseline
ngiographic characteristics were similar between random-
zed treatment groups with the exceptions that SVG age was
lightly older for Interceptor-treated patients and baseline
IMI flow grades were slightly less in control-treated
atients (Table 2). The extent of saphenous vein graft
egeneration was also similar between groups. Approxi-
ately 20% of patients in both treatment groups had
xtensive (50% graft length) degeneration.
rocedural details. Of the 797 enrolled patients, 4 patients
id not have a procedure performed and 8 did not have the
ssigned treatment strategy attempted. No differences in any
rocedural parameters were observed between randomly
ssigned treatment groups (Table 3). Approximately 40% of
atients in both groups received periprocedural GP IIb/IIIa
nhibitor therapy, and a similar portion of each group
eceived treatment with DES (vs. BMS). Device success in
he Interceptor group (90.5%; 478 of 528) was similar to
hat in controls (93.8%; 241 of 257; p  0.134). Clinical
uccess was similar in the Interceptor (85.4%, 451 of 528)
nd control groups (86.8%; 230 of 257; p  0.118).
ostprocedure in-stent minimal lumen diameter and per-
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253ent diameter stenosis were slightly larger in the Interceptor
reatment group. The final TIMI flow grade was 3 in 98.1%
528 of 538) of Interceptor and 97.4% (267 of 271) of
ontrol patients. Similarly, no differences in the incidence of
o-reflow, abrupt vessel closure, or distal embolization were
bserved between treatment groups.
n-hospital and 30-day clinical outcomes. No differences
etween treatment groups were observed with respect to
n-hospital outcomes (Table 4). Similarly, to 30 days’
ollow-up, no differences were observed in any adverse
linical events with the exception that target vessel revascu-
arization (TVR) of a nontarget lesion was slightly more
revalent (p  0.04) in control device-treated patients
ompared with the Interceptor group. These revasculariza-
ion events involved the distal SVG site of device deploy-
ent and occurred within 12 h and 26 days after Guard-
ire (n  2) and at 17 days after FilterWire EZ (n  1)
reatment, respectively. Target vessel revascularization of a
ontarget lesion was not observed after Interceptor treat-
ent. Angiographic core lab determined target vessel ref-
rence diameters were for patients who incurred this adverse
vent were 2.10 and 1.61 mm in the GuardWire and 3.45
m in the FilterWire-treated patient, respectively. Clinical
vents associated with TVR of a nontarget lesion included
on–Q-wave MI (n  1) and unstable angina (n  2).
The primary end point of 30-day MACE (Table 4)
nalyzed on patients with available follow-up (25 days
fter procedure or incidence of MACE by 30 days) occurred
t a rate of 8.0% (40 of 501) in the Interceptor group and
Table 1. Baseline Clinical Characteristics
Interceptor
(n  533 Patients)
Control
(n  264 Patients)
p
Value
Age, yrs 69.04  10.22 68.25  10.37 0.305
Male, % 79.4 78.0% 0.712
Canadian Cardiovascular
Society angina class, %
0.744
None 9.1 9.2% 0.744
I 10.1 11.3%
II 29.5 26.7%
III 23.9 23.3%
IV 27.4 29.6%
Peripheral vascular disease, % 29.7 27.6% 0.612
Dyslipidemia, % 91.3 93.2% 0.409
Hypertension, % 86.1 87.9% 0.509
Diabetes, % 45.1 43.6% 0.705
Prior stroke, % 10.4 8.8% 0.528
Current smoker, % 22.2 17.9% 0.269
Myocardial infarction, % 60.8 54.7 0.113
Prior PCI, % 10.3 10.9% 0.805
Left ventricular ejection
fraction, %
50.7  11.6 51.6  11.5 0.325
PCI percutaneous coronary intervention..3% (18 of 247) in the control group, yielding a riskifference of 0.7% (upper 1-sided 95% CI of 4.0% by the
arrington-Manning approach). This upper CI was less
han the noninferiority margin of 4.5% and indicates that
he Interceptor device met noninferiority criteria when
ompared with the control (p  0.025). This analysis was
epeated on the entire ITT population (n  533 Intercep-
or; n  264 control) with multiple imputation used to
stimate 30-day MACE incidence for patients who were
rematurely withdrawn and yielded similar results (upper
-sided 95% CI of 4.3%). Similarly, analysis of the PP
opulation which included 719 patients (735 lesions), of
hom 478 were successfully treated with the Interceptor
nd 241 were successfully treated with control (172 Guard-
ire, 69 FilterWire EZ), demonstrated MACE to 30 days
n 6.2% of Interceptor and 6.3% of control patients, yielding
n upper-bounded 95% CI of 3.0% (well less than the
Table 2. Baseline Angiographic Characteristics
Interceptor
(n  533 Patients)
(n  541 Lesions)
Control
(n  264 Patients)
(n  272 Lesions)
p
Value
SVG age, yrs 11.10 5.66 10.34 5.57 0.08
SVG distribution, % 0.605
LAD 18.7 18.5%
LCX 37.5 41.0%
RCA 43.8 40.6%
SVG lesion location, % 0.277
Ostial 12.8 16.2%
Proximal 35.1 38.4%
Mid 40.6 36.2%
Distal 11.5 9.2%
Lesion length, mm 14.28 9.73 14.45 9.39 0.813
Reference diameter, mm 3.27 0.69 3.22 0.62 0.288
Minimal luminal diameter, mm 1.14 0.55 1.14 0.58 0.823
Diameter stenosis, % 65.24 14.56 65.20 14.94 (271) 0.965
Bend, degrees 26.53 18.92 25.57 18.29 (271) 0.490
Lesion angulation, % 0.397
0°–44° 94.8 82.7%
45°–90° 12.4 14.4%
90° 2.6 3.0%
Thrombus score, % 0.574
0 30.2 28.8%
1 40.4 46.5%
2 17.1 15.1%
3 11.5 8.1%
4 0.4 1.5%
Tortuosity, % 5.2 3.0% 0.205
Calciﬁcation, % 13.2 11.1 0.431
TIMI ﬂow grade 0.033
0/1 0.7 1.1%
2 7.8 12.2%
3 91.5 86.7%
LAD left coronary descending; LCX left coronary circumflex; RCA right coronary ascending;SVG saphenous vein graft; TIMI Thrombolysis In Myocardial Infarction.
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254oninferiority margin of 4.5%; noninferiority p  0.023.
here was no significant interaction between treatment
ssignment and prerandomization intended use of GP
Ib/IIIa inhibitors on 30-day MACE (p  0.569).
iscussion
ercutaneous coronary intervention of degenerative SVGs is
omplicated by adverse ischemic events, particularly myo-
ardial infarction, because of distal embolization of athero-
hrombotic debris and microvascular occlusion (1,4,8–12).
he risk of atheroembolism may be increased in proportion
o the age and extent of SVG degeneration, plaque burden
determined by conduit diameter and lesion length), as well
s the presence of thrombus (19,20). The use of an embolic
rotection device during SVG interventions is associated
ith a significant reduction in adverse clinical events (vs. no
mbolic protection) and, hence, has been accorded a Class 1
ecommendation in the current American College of Car-
iology/American Heart Association guidelines for the
erformance of PCI (11–15,21).
Several strategies for embolic protection exist and include
Table 3. Procedural Outcomes and Angiographic Res
Inte
(n  53
Procedure duration, min 41.15
Device success, %
Clinical success, %
GP IIb/IIIa inhibitors used, %
Stents implanted, %
DES, %
BMS, %
Stents per patient, n 1.28
Total length of stents, mm 25.81
Maximal balloon or stent diameter, mm 3.81
Maximal inﬂation pressure, atm 16.43
Reference vessel diameter, mm 3.27
Minimal luminal diameter, mm
In lesion 2.78
In stent 3.51
Diameter stenosis, %
In lesion 15.20
In stent 7.7
Final TIMI ﬂow grade, %
0/1
2
3
Thrombus, %
Dissection, %
Distal embolus, %
Perforation
BMS bare-metal stent(s); DES drug-eluting stent(s); GP glycopristal conduit occlusion and aspiration as well as distal filter Sevices (12,22). Limited available data suggest that both the
fficiency and size of particulate debris capture is similar
etween occlusion and filter devices (23). Distal occlusion
nd aspiration may offer the potential advantage of remov-
ng humoral factors (both lesion and platelet derived) that
romote microvascular spasm (24). Alternatively, filter de-
ices that maintain conduit flow may be symptomatically
nd hemodynamically better tolerated by the patient and
rovide angiographic visibility of the target lesion(s) during
CI. Filter devices may differ in crossing profile and ability
o atraumatically circumferentially oppose the target conduit
s well as in open pore area available to provide flow and
apture debris (15). Indeed, open-pore area (that portion of
he expanded filter which is composed of pores) appears to
e a critical determinant of both flow and capacity to
apture debris without becoming obstructed. Despite the
vailability of randomized controlled trial data demonstrat-
ng efficacy for embolic protection in reducing periproce-
ural MACEs and the commercial availability of multiple
mbolic-protection devices, an embolic-protection strategy
s used in only a minority (30%) of patients undergoing
or
ients)
Control
(n  264 Patients) p Value
.26 42.13  42.09 0.618
93.8 0.134
86.8 0.118
39.4 0.939
98.8 1.000
61.7 0.588
38.3
8 1.39  0.78 0.033
.28 27.20  15.73 0.260
3 3.83  0.98 0.841
9 16.20  4.00 0.332
9 3.22  0.62 0.288
0 2.72  0.60 0.152
2 3.40  0.65 0.019
9 16.24  10.37 0.189
.05 5.46  14.26 0.020
0.490
0.7
1.8
97.4
4.0 0.414
2.2 0.815
0.7 1.000
0.4 1.000
IMI Thrombolysis In Myocardial Infarction.ults
rcept
3 Pat
 23
90.5
85.4
40.0
98.5
59.4
40.6
 0.5
 16
 1.1
 3.3
 0.6
 0.6
 0.6
 8.0
7  11
0.0
1.9
98.1
3.0
2.8
0.9
0.2VG-PCI (25). This apparent lack of use remains unex-
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255lained but may, at least in part, be due to the relative
omplexity of operator use for available devices. The pur-
ose of the present study was to evaluate the relative safety
nd efficacy of a novel guidewire based filter distal embolic
rotection device, when compared with devices which were
ommercially available at the time of study enrollment.
rom this study, several important observations can be
ade.
First, the Interceptor PLUS filter system was demon-
trated to be not inferior to the control embolic protection
evice(s) with respect to the occurrence of MACE to 30
ays in both the primary (ITT) analysis as well as the
econdary (PP-treated) subgroup analyses. No difference in
he occurrence of any adverse clinical event was observed
etween randomly assigned treatment groups (Interceptor
Table 4. Major Adverse Cardiac Events in Hospital and to 30 Days
Interceptor
(n  533 Patients)
Control
(n  264 Patients) p Value
In-hospital
MACE, % 7.3 5.7 0.455
Death 0.0 0.8 0.109
Myocardial infarction 7.3 5.3 0.365
Q-wave 0.4 0.8 0.603
Non–Q-wave 6.9 4.5 0.212
Emergent CABG 0.0 0.0
TLR 0.0 0.0
TVR 0.0 0.4 0.331
TVF 7.3 5.7 0.455
Stent thrombosis 0.0 0.0
Perforation 0.9 1.1 0.724
Vascular complications 2.3 3.0 0.482
Bleeding
complications
2.6 3.8 0.383
Stroke 0.2 0.0 1.000
30 days
MACE, % 8.0 7.3 0.774
Death 0.0 0.8 0.109
Myocardial infarction 8.0 6.1 0.376
Q-wave 0.4 0.8 0.602
Non–Q-wave 7.6 5.3 0.281
Emergent CABG 0.0 0.0
TLR 0.2 0.4 0.552
TVR 0.0 1.6 0.043
TVF 8.0 7.3 0.774
Stent thrombosis 0.4 0.8 0.602
Perforation 0.8 1.2 0.690
Vascular complications 2.6 3.6 0.491
Bleeding
complications
3.0 4.0 0.517
Stroke 0.2 0.0 1.000
CABG coronary artery bypass grafting; MACEmajor adverse cardiac event (defined as death,
myocardial infarction, emergent CABG, and TVR); TLR  target lesion revascularization; TVF 
target vessel failure; TVR target vessel revascularization not involving the target lesion.s. control) with the exception that TVR of a nontarget pesion was observed slightly more frequently among control
evice treated patients (1.2% vs. 0% Interceptor respectively;
 0.04). In addition, no differences were observed in
ither device or clinical procedural success. Furthermore,
here was consistency of the treatment effect of the Inter-
eptor device compared with control devices across GP
Ib/IIIa-treated and -untreated patients. This observation is
onsistent with both the lack of apparent GP IIb/IIIa
eceptor inhibitor benefit for either GuardWire or Filter-
ire EZ treated patients in both the SAFER and FIRE
rials (13,14), as well as the overall lack of GP IIb/IIIa
enefit during SVG PCI previously reported from multiple
andomized, placebo controlled trials (19,26,27).
Although the ability of GP IIb/IIIa receptor blocking
gents to disaggregate platelet-rich thrombus (28) has
ntuitive theoretic appeal to prevent filter pore plugging and
nhance filter efficiency, no objective clinical or angio-
raphic data support this premise. The lack of GP IIb/IIIa
nhibitor benefit has been attributed to the possibility that
latelet inhibition may be overwhelmed when large amounts
f prothrombotic embolic material are present or conversely,
hat periprocedural ischemic events during SVG-PCI may
ot be thrombus related but instead due to the friable
articulate debris characteristic of older SVG atherosclerotic
esions (19,22,27).
Given the friability of aging SVGs, there is a potential
oncern for placement of any distal protection device
hrough and beyond the target lesion. In this regard, the
rend toward less frequent TVR (of nontarget lesions) to 30
ays among Interceptor compared with control device
reated patients is noteworthy. Although the numbers of
vents are small (3 in control vs. 0 in Interceptor) and could
e due to chance, both the nature and time-course of these
vents are clinically relevant. In each case, angiographic
vidence of endoluminal disruption was evident in the
egion of distal graft where device deployment occurred. As
evice deployment occurs distal (25 to 35 mm) to target
esion, the small target vessel reference diameters of 2.10
nd 1.61 mm in the GuardWire-treated patients are note-
orthy and suggest caution for device deployment in smaller
aliber conduits. Endoluminal trauma due either to device
xpansion or traction on the device during stent deployment
r device retrieval may have occurred.
It is of some concern that the overall incidence of MACE
o 30 days in distal embolic protection device-treated
atients in this trial appears to be less than in previous trials
n which the control devices (GuardWire, FilterWire EZ)
ere evaluated (13,14). Indeed, GuardWire-treated patients
nrolled into the SAFER trial experienced a 9.6% incidence
f MACE to 30 days using a similar definition as was
mployed in the current study (13). Similarly, MACE to 30
ays was observed in 11.6% of GuardWire and 9.9% of
ilterWire-treated patients in the FIRE trial (14). These
recedent observations prompted the 10% MACE rate
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256ssumption used in the original AMEthyst study sample
ize calculation. After enrollment and prespecified interim
nalysis of the first 300 patients in the AMEthyst trial, a
ignificantly lower primary end point event rate (6%) was
bserved and prompted expansion of trial enrollment from
00 to 800 patients. This observation has important impli-
ations for the design of future SVG intervention trials.
otential explanations for this finding include differences in
he SVG disease being treated or in the type and prevalence
f adjunctive pharmacotherapy as well as in the type of stent
evices deployed. Preliminary comparisons suggest no sig-
ificant differences exist between GuardWire-treated pa-
ients enrolled into the SAFER trial and the AMEthyst trial
ith respect to reference target vessel diameter, lesion
ength, or plaque burden. Although the prevalence of
latelet GP IIb/IIIa inhibitor use was more frequent in the
AFER (60%) compared with the AMEthyst (40%)
rial, fewer patients in the SAFER trial had adequate
retreatment with either statins or clopidogrel, which have
een demonstrated to reduce periprocedural ischemic
vents, particularly enzymatic infarction (29,30).
Finally, iterative evolution in available BMS and DES
latforms has occurred, which could influence the occur-
ence of early (30 day) events. The AMEthyst is the first
arge-scale randomized trial of embolic protection in which
atients could receive any FDA-approved stent whether
ES or BMS. Of note, DES were deployed in 60% of
atients enrolled into AMEthyst. Stent thrombosis through
0 days was observed in 0.4% of DES- and 0.7% of
MS-treated patients, respectively. The variety and distri-
ution of stent type deployed in AMEthyst differs from
hose used in both the SAFER and FIRE trials and may, in
art, contribute to the apparent differences in clinical end
oints observed.
tudy limitations. Several limitations of the current study
eserve mention. First, iterative device evolution resulted in
esign improvements being incorporated into the study
evice early in the trial. The design improvements made in
he Interceptor PLUS (compared with the Interceptor P2
evice) were in large part related to operator ease of use (no
elivery or retrieval sheath), simplified device deployment
ith the actuator handle and monorail catheter compatibil-
ty. There were no differences between these devices in filter
ore size or open-pore area. Furthermore, the validity of
ooling Interceptor P2 (n  54) and Interceptor PLUS (n
 479) treated patients is supported by the absence of
ignificant difference in any clinical outcomes between these
reatment groups.
Second, the original study sample size calculation used an
ssumption of primary end point event occurrence rate
10%) based on available precedent randomized controlled
rials. The remarkable lower incidence of event rate occur-
ence observed after the enrollment of the first 300 patients
equired trial enrollment expansion (from 600 to 800atients) to provide adequate statistical power and a more
tringent noninferiority delta than used in the FIRE trial
4.5% vs. 5.5% respectively). Several potential explanations
or the lower-than-expected event rate exist, of which the
revalence of background adjunctive pharmacologic pre-
reatment (particularly with clopidogrel and statin therapy)
ppears most plausible. Importantly, the appropriate adjust-
ent in sample size was made without study unblinding to
rovide adequate statistical power to the primary end point
bservations.
Third, assignment to the control device (GuardWire vs.
ilterWire EZ) was not randomized, and pooling of these
evices was performed to provide an aggregate control
evice event rate. Pooling of control devices is supported by
he lack of difference in any clinical endpoint through 30
ays between these nonrandomly assigned groups. In this
espect, the introduction, relative ease of use, and rapid
linical adoption of the FilterWire EZ embolic protection
evice after conception of the AMEthyst trial severely
imited trial enrollment and mandated inclusion of this
evice to maintain clinical relevance of the primary end
oint comparisons.
Finally, as more devices have become FDA approved and
ommercially available, the selection of a single device to
erve as an active control in a randomized trial comparison
as become progressively difficult. Indeed, it could be
rgued that the comparison of a novel device with the
vailable devices allows a more clinically relevant compari-
on to current standards of care.
onclusions
his study demonstrates that safety and efficacy of the novel
nterceptor PLUS Coronary Filter System for distal embolic
rotection during PCI of degenerative SVG is similar to
hat of commercially available devices (GuardWire; Filter-
ire EZ) to 30 days after procedure. A trend toward
ess-frequent TVR of nontarget lesions to 30 days was
bserved in Interceptor PLUS-treated patients.
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